Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India
- 9 May 2008
- journal article
- research article
- Published by Taylor & Francis in Australian Journal of International Affairs
- Vol. 62 (2) , 196-213
Abstract
This article compares controversial health technology provisions in two important United States free trade agreements with developed nations: Australia and with South Korea. It examines the multinational corporate forces behind the medicines and medical devices components of these texts and their likely impacts upon Australian trade negotiations with China and India. It also examines the implications of some recent changes to US trade policy for this area in subsequent bilateral deals such as that with Peru. This article argues it is important that the Australian government change policy and, like the present Congress in the United States, now systematically approach such impending trade agreements with a view to assisting the partners’ regulatory frameworks to maximally enhance national and transnational benefit from their medicines and biotechnology industries.Keywords
This publication has 9 references indexed in Scilit:
- Drug price reforms: the new F1–F2 bifurcationAustralian Prescriber, 2007
- Reference pricing for pharmaceuticals: is the Australia–United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?Medical Journal of Australia, 2007
- Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewalAustralia and New Zealand Health Policy, 2007
- 'Linkage' pharmaceutical evergreening in Canada and AustraliaAustralia and New Zealand Health Policy, 2007
- The global biopharma industry and the rise of Indian drug multinationals: implications for Australian generics policyAustralia and New Zealand Health Policy, 2007
- Foreign free riders and the high price of US medicinesBMJ, 2005
- Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policyGlobalization and Health, 2005
- Will the Australia–United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?Medical Journal of Australia, 2004
- The subsidy of pharmaceuticals in Australia: processes and challengesAustralian Health Review, 2004